← All trials
NCT03635983
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 14, 2018
- Primary completion
- Aug 15, 2023
- Completion date
- Mar 15, 2025
- First posted
- —
- Last posted
- —
- Enrollment
- 764
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Bristol-Myers SquibbLead sponsor
- Nektar TherapeuticsCollaborator
- Bristol-Myers SquibbOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.